Similar Search Results

Regulating Ambiguous Risks : The Less than Rational Regulation of Pharmaceuticals

Viscusi, W. Kip; Zeckhauser, Richard J. - 2015

The U.S. Food and Drug Administration (FDA) balances risks and benefits before approving pharmaceuticals, as …

Persistent link: https://www.econbiz.de/10014148944

Parallel Trade in Pharmaceuticals : Trade Therapy for Market Distortions

Abbott, Frederick M. - 2017

, particularly from an economic standpoint. In this regard, pharmaceuticals are not generally traded in what might be described as a … because it is imported. Parallel trade (i.e., imports and exports) in pharmaceuticals takes place in markets that are … international exhaustion. This should help to facilitate price reductions in the global market for pharmaceuticals …

Persistent link: https://www.econbiz.de/10014124812

Optimal Patent Policy for Pharmaceutical Industry

Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2020

We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about generic producers' responses to changes in the effective duration and scope of new drug patents. To estimate these responses, we use data on Paragraph IV patent challenges, and two...

Persistent link: https://www.econbiz.de/10014097057

International Price Regulations in the Pharmaceutical Sector : A Common Model to Sharing the Benefits

Levaggi, Rosella; Capri, Stefano - 2005

In this article we analyse the market for drugs in health care markets where third payers (an insurance company or a government agency) bear the cost and we suggest a common and transparent methodology to set the price for new drugs as well as active principles for which an alternative already...

Persistent link: https://www.econbiz.de/10014028693

Self-Exclusion

Leitzel, Jim - 2011

Gambling jurisdictions around the world have adopted self-exclusion programs in which gamblers can voluntarily agree to be barred from further gambling. The popularity of self-exclusion stems from its aid in combating problem or pathological gambling, along with its non-coercive nature. To...

Persistent link: https://www.econbiz.de/10014218567

India's Trade-Related Aspects of Intellectual Property Rights Compliant Pharmaceutical Patent Laws : What Lessons for India and Other Developing Countries?

Sundaram, Jae - 2014

India's trade-related aspects of Intellectual Property Rights (TRIPS) compliant Patent (Amendment) Act 2005 saw the transformation of its laws from a process patent regime to a product patent regime. The amendments have had a direct impact on India's generic drugs manufacturing sector, which was...

Persistent link: https://www.econbiz.de/10013051966

Is medicines parallel trade "regulatory arbitrage"?

Costa-Font, Joan - 2015

In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...

Persistent link: https://www.econbiz.de/10010477153

Sin licenses revisited

Haavio, Markus; Kotakorpi, Kaisa - 2012

We analyse attempts to implement personalised regulation in the form of sin licenses (O'Donoghue and Rabin 2003, 2005, 2007) to correct the distortion in the consumption of a harmful good when consumers suffer from varying degrees of self-control problems. We take into account the possibility...

Persistent link: https://www.econbiz.de/10009683333

Ho, Cynthia M. - 2021

Forty percent of spiraling US drug costs are based on a mere two percent of all drugs –biologic drugs (biologics) made from living cells that are administered by injection or infusion. These costs will continue to balloon as new biologics are approved; the recently approved Alzheimer’s drug is...

Persistent link: https://www.econbiz.de/10014087594

Drug quality and safety issues in India

Chokshi, Maulik; Mongia, Rahul; Wattal, Vasudha - 2015

Today, the global pharmaceutical product value chain is becoming increasingly complex and this has led to the emergence of 'multiple quality standards' for medicines. But this non-uniformity in the quality of medicine is also contingent upon both the regulatory milieu in the country of...

Persistent link: https://www.econbiz.de/10011337690